Compare Strategy Inc. (MSTR) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Tilray Brands Inc — how do they compare? Strategy Inc. trades at $154.34 (market cap $60.40B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Strategy Inc. is far larger — about 113.8× Tilray Brands Inc's market cap, and Strategy Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Tilray Brands Inc for 31 Days on average.
| MSTR | TLRY | |
|---|---|---|
Market Cap | $60.40B | $530.54M |
Volume | 23,421,830 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $320.29 | $21.00 |
52-Week Low | $82.31 | $3.57 |
Typical Hold Time | 112 Days | 31 Days |
Enterprise Value | $79.16B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $154.34, up 0.63% with a bullish technical signal and strong analyst support. The company shows concerning fundamentals with negative net income margins of -6,102.96% and three consecutive earnings misses, though revenue remains stable around $477 million. Recent news highlights Citigroup's upgraded price target to $240 and the stock's 35% monthly surge, positioning it as a high-risk, high-reward play tied to Bitcoin market movements despite operational challenges.
Outlook remains polarized: 62% analyst buy ratings and a $253 consensus target suggest 64% upside, but extreme profitability risks and volatile cash flows demand caution. Investment opportunity hinges on Bitcoin's performance amplifying equity value, while risks include persistent losses, debt burden, and sensitivity to crypto market swings.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
